For the third quarter of the fiscal year ending March 2026, revenue was JPY 210.8 billion (5.4% YoY decline), operating income was JPY 28.2 billion (19.8% YoY decline), and net income attributable to owners of the parent for the quarter was JPY 21.8 billion (20.6% YoY decline).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4536","jir_company_name":"Santen Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-02-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4536-20260205-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, revenue was JPY 210.8 billion (5.4% YoY decline), operating income was JPY 28.2 billion (19.8% YoY decline), and net income attributable to owners of the parent for the quarter was JPY 21.8 billion (20.6% YoY decline).","jir_summary":"### Performance Overview\nFor the third quarter of the fiscal year ending March 2026, consolidated revenue was JPY 210.8 billion, down 5.4% year-over-year, operating income was JPY 28.2 billion, down 19.8%, and net income attributable to owners of the parent for the quarter was JPY 21.8 billion, down 20.6%. The results were affected by drug price revisions and inventory adjustments in distribution channels; however, efforts focusing on new and core products resulted in progress in line with the full-year forecast. Regionally, Japan declined by 12.4%, China was roughly flat YoY, while Asia excluding China and EMEA showed growth trends. R&D expenses increased by 9.5% YoY, and amortization of intangible assets related to products remained nearly flat compared with the previous year.\n\n### Financial Position and Cash Flow Status\nAt the end of the third quarter, total assets amounted to JPY 401.2 billion, decreasing compared to the previous year, total equity was virtually unchanged at JPY 282.4 billion, liabilities decreased to JPY 118.7 billion, and the equity ratio attributable to owners of the parent rose by 0.7 points to 70.6%. Cash flow from operating activities was an inflow of JPY 22.5 billion, down compared to the previous year. Cash outflows from investing activities totaled JPY 11.6 billion and financing activities outflowed JPY 47.8 billion. The reduction in shares outstanding due to treasury stock retirement affected basic earnings per share, but there is no change to the dividend forecast.","jir_financial_highlights":"Revenue: JPY 210,763 million (5.4% YoY decline)\nCore Operating Income: JPY 34,793 million (20.3% YoY decline)\nOperating Income: JPY 28,219 million (19.8% YoY decline)\nQuarterly Profit: JPY 21,998 million (19.6% YoY decline)\nNet Income Attributable to Owners of Parent for the Quarter: JPY 21,816 million (20.6% YoY decline)\nTotal Assets: JPY 401,161 million (Approximately 2.0% YoY decline)\nTotal Equity: JPY 282,436 million (Virtually flat YoY)\nEquity Ratio Attributable to Owners of Parent: 70.6% (0.7 points YoY increase)\nBasic Quarterly Earnings Per Share: JPY 66.16 (Decrease YoY (JPY 78.21 \u2192 JPY 66.16))\nFull-Year Revenue Forecast: JPY 294,000 million (2.0% YoY decline)\nFull-Year Operating Income Forecast: JPY 44,000 million (6.1% YoY decline)\nFull-Year Net Income Attributable to Owners of Parent Forecast: JPY 34,000 million (6.2% YoY decline)\nAnnual Dividend (Forecast): JPY 38.00 (Increase YoY (JPY 36.00 \u2192 JPY 38.00))\nShares Outstanding at Period-End (Including Treasury Stock): 322,273,954 shares (Decrease YoY (342,055,554 shares \u2192 322,273,954 shares))\nTreasury Shares at Period-End: 602,370 shares (Decrease YoY (691,515 shares \u2192 602,370 shares))","jir_category":"","jir_hashtags":"#SantenPharmaceuticalCoLtd, #financial_summary, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Revenue: JPY 210,763 million (5.4% YoY decline)\nOperating Income: JPY 28,219 million (19.8% YoY decline)\nNet Income Attributable to Owners of Parent for the Quarter: JPY 21,816 million (20.6% YoY decline)","jir_meta_title":"Santen Pharmaceutical FY March 2026 Q3 Financial Summary Revenue JPY 210.8 Billion Down 5.4% YoY","jir_meta_description":"Santen Pharmaceutical Co., Ltd. releases its FY March 2026 Q3 Financial Summary reporting revenue of JPY 210.8 billion (5.4% YoY decline), operating income of JPY 28.2 billion (19.8% decline), and net income attributable to owners of parent of JPY 21.8 billion (20.6% decline). Dividend forecast maintained at JPY 38.","jir_og_title":"Santen Pharmaceutical FY2026 Q3 Financial Results Revenue Decline but Progress on Plan","jir_og_description":"Santen Pharmaceutical\u2019s FY March 2026 Q3 Financial Summary shows revenue of JPY 210.8 billion, operating income of JPY 28.2 billion, and net income attributable to owners of parent of JPY 21.8 billion. Dividend forecast remains unchanged at JPY 38.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[222773,210763],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[35195,28219],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"quarterly_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent for the Quarter Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income Attributable to Owners of Parent for the Quarter\\\",\\\"data\\\":[27465,21816],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Region (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan\\\",\\\"China\\\",\\\"Asia (Excluding China)\\\",\\\"EMEA\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY March 2026 Q3\\\",\\\"data\\\":[104800,23100,23700,58200],\\\"backgroundColor\\\":[\\\"#007bff\\\",\\\"#28a745\\\",\\\"#ffc107\\\",\\\"#dc3545\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"profit_margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Quarterly Net Income Margin Attributable to Owners of Parent as % of Revenue\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Margin\\\",\\\"data\\\":[12.3,10.4],\\\"borderColor\\\":\\\"#17a2b8\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true,\\\"max\\\":15}}}}\"}]","ir_related_company":7842,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-24646","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n